A Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease (PRECIZN-1)

  • End date
    Aug 9, 2024
  • participants needed
  • sponsor
    Bioverativ, a Sanofi company
Updated on 8 April 2022
cell transplantation
acute chest syndrome
chest syndrome
sickle hemoglobin


This is an open label, multicenter, Phase 1/2 study in approximately eight adults with severe Sickle Cell Disease (SCD). The study will evaluate the safety, tolerability, and efficacy of autologous hematopoietic stem cell transplantation using BIVV003.


Subject participation in this study will be approximately 136 weeks. Enrolled subjects will be asked to participate in a separate long-term follow-up study to monitor the safety and efficacy of BIVV003 treatment for a total of 15 years post-transplant.

Condition Sickle Cell Disease
Treatment busulfan, Plerixafor, BIVV003
Clinical Study IdentifierNCT03653247
SponsorBioverativ, a Sanofi company
Last Modified on8 April 2022


Yes No Not Sure

Inclusion Criteria

Ages 18 to 40
Confirmation of sickle cell disease (SCD) diagnosis (HbSS or HbS[beta]0 genotype)
Severe SCD, defined as having 1 or more of the following manifestations: Clinically significant neurologic event (example [e.g.], stroke) or any neurological deficit lasting more than 24 hours; History of 2 or more episodes or Acute Chest Syndrome (ACS) in 2 years prior to informed consent (despite adequate supportive therapies such as asthma therapy); Six or more pain crises per year in 2 years prior to informed consent (requiring intravenous [IV] pain management in the outpatient or inpatient hospital setting); History of 2 or more cases or priapism with participant seeking medical care in the 2-years prior to informed consent; Regular RBC transfusion therapy in the year prior to informed consent (having received 8 or more transfusions to prevent vaso-occlusive clinical complications); and Echocardiographic finding of tricuspid valve regurgitant jet (TRJ) velocity of greater than or equal to 2.5 meter per second (m/s)
Clinically stable to undergo stem cell mobilization and myeloablative hematopoietic stem cell transplantation (HSCT)
Adequate physiological function, defined as the following: Karnofsky/Lansky Performance of greater than or equal to 60; Acceptable cardiac function as defined in protocol; Acceptable pulmonary function as defined in protocol; Acceptable renal function as defined in protocol; and Acceptable hepatic function as defined in protocol
Ability to understand purpose and risks of study, provide Informed Consent Form (ICF) and authorization to use protected health information
Completion of age-appropriate cancer screening
Willingness to use double-barrier method of contraception through entire study period (for participants of childbearing potential)
Willingness to receive blood transfusions
Willingness to discontinue hydroxyurea (HU) at least 30 days prior to stem cell mobilization through Day 100 post-transplantation

Exclusion Criteria

Previous receipt of an autologous or allogeneic HSCT or solid organ transplantation
Previous treatment with gene therapy
Current enrollment in an interventional study or having received an investigational drug within 30 days of study enrollment
Pregnant or breastfeeding female
Female or male who plans to become pregnant or impregnate a partner, respectively, during the anticipated study period
Contraindication to plerixafor, apheresis, or busulfan
Treatment with prohibited medication in previous 30 days
Known allergy or hypersensitivity to plerixafor, busulfan, or investigational product excipients
History of active malignancy within past 5 years, any history of hematologic malignancy, or a family history of a cancer predisposition syndrome (without negative result of candidate)
Current diagnosis of uncontrolled seizures
History of significant bleeding disorder
Clinically significant infection
Any major organ dysfunction involving brain, kidney, liver, lung, or heart (e.g., congestive heart failure, pulmonary hypertension)
Corrected QT interval of more than 500 millisecond (ms) based on screening electrocardiogram (ECG)
Positive for human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV)
Known to have a gamma-globin variant associated with altered oxygen affinity
Hereditary persistence of fetal hemoglobin (HPFH) or HbF concentration of more than or equal to 20 percent (%) at screening
Absolute Neutrophil Count (ANC) of less than or equal to 1,000 per microliter
Platelet count of less than 100,000 per microliter
History of platelet alloimmunization (precluding ability to provide transfusion support)
Extensive Red Blood Cell (RBC) alloimmunization (precluding ability to provide transfusion support)
Judged unsuitable for participation by investigator and/or sponsor
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note